학술논문
Anticoagulation ant antiplatеlet therapy in patients with COVID-19 infection
Document Type
Academic Journal
Author
Source
Bulgarian Cardiology. October 18, 2021 Issue 3, p24, 6 p.
Subject
Language
English
ISSN
1310-7488
Abstract
Author(s): Zheyna Cherneva (corresponding author) [1]; Radostina Cherneva [2] Author Note(s): Corresponding author: Zheyna Cherneva (jenicherneva@yahoo.com). Academic editor: Nikolay Runev DOI: [...]
COVID-19 infection is characterized with hyperstimulated inï¬ ammatory response that affects lungs, cytokine storm and acute respiratory distress syndrome. Thrombotic complications are the leading reason for death in COVID-19 patients. Those of them with previous cardio-vascular diseases or risk factors - obesity, arterial hypertension, diabetes mellitus, advanced age are with higher risk for worse clinical outcome. Coagulopathy as well as thrombocytopathy and endothelial dysfunction are signiï¬ cant pathophysiological factors for the severe clinical course of the infection. Beside anticoagulation therapy, targetеd strategies regarding thrombocytopathy and endothelial dysfunction are necessary for the treatment of patients with COVID-19 infection.
COVID-19 infection is characterized with hyperstimulated inï¬ ammatory response that affects lungs, cytokine storm and acute respiratory distress syndrome. Thrombotic complications are the leading reason for death in COVID-19 patients. Those of them with previous cardio-vascular diseases or risk factors - obesity, arterial hypertension, diabetes mellitus, advanced age are with higher risk for worse clinical outcome. Coagulopathy as well as thrombocytopathy and endothelial dysfunction are signiï¬ cant pathophysiological factors for the severe clinical course of the infection. Beside anticoagulation therapy, targetеd strategies regarding thrombocytopathy and endothelial dysfunction are necessary for the treatment of patients with COVID-19 infection.